Schrödinger is discontinuing the development of its blood cancer CDC7 inhibitor after two patient deaths. In a Phase I trial ...

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

During a live event, Andrew H. Lipsky, MD, and participants debate BTK plus BCL2 inhibitor benefits, barriers, and optimal ...

Thousands of Medicare recipients will face higher costs for expensive cancer drugs following passage of two provisions in the One Big Beautiful Bill Act, signed by President Donald Trump in July, The ...

July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment ...

Q2 2025 Earnings Call Transcript July 31, 2025 AbbVie Inc. beats earnings expectations. Reported EPS is $2.97, expectations were $2.88. Operator: Good morning, and thank you for standing by. Welcome ...

AbbVie Inc (ABBV) surpasses expectations with robust sales from Skyrizi and Rinvoq, while navigating Humira declines and ...

AbbVie Inc. ABBV reported second-quarter 2025 adjusted EPS of $2.97, which beat the Zacks Consensus Estimate of $2.89. The reported figure also exceeded the company’s guidance of $2.84-$2.88 issued ...

Reports Second-Quarter Diluted EPS of $0.52 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.97, an Increase of 12.1 Percent; These Results ...

AbbVie announced the global Phase 3 VERONA trial evaluating Venclexta (venetoclax) in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (MDS ...

AbbVie Inc. lost its challenge against the US Patent and Trademark Office over disputed patent term adjustments for its Venclexta cancer drug.